{
  "cik": 1691082,
  "cik_padded": "0001691082",
  "entityName": "LB PHARMACEUTICALS INC",
  "fiscal_years": [
    {
      "accn": "0001193125-26-126368",
      "filed": "2026-03-26",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 52000.0,
        "cash": 250173000.0,
        "eps_diluted": -3.13,
        "free_cash_flow": -35260000.0,
        "net_income": -25205000.0,
        "operating_cash_flow": -35208000.0,
        "stockholders_equity": 301310000.0,
        "total_assets": 312934000.0,
        "total_liabilities": 11624000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.038578208489595436,
        "roa_avg2y": -0.1454968424212337,
        "roa_period_end": -0.0805441402979542,
        "roe_avg2y": -0.24381396428640523,
        "roe_period_end": -0.0836513889349839
      }
    },
    {
      "accn": "0001193125-26-126368",
      "filed": "2026-03-26",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 769000.0,
        "cash": 22978000.0,
        "eps_diluted": -176.15,
        "free_cash_flow": -53821000.0,
        "net_income": -63102000.0,
        "operating_cash_flow": -53052000.0,
        "stockholders_equity": -94554000.0,
        "total_assets": 33534000.0,
        "total_liabilities": 13829000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_period_end": -1.8817319735194133,
        "roe_avg2y": 0.9781208584249809
      }
    },
    {
      "accn": "0001193125-26-126368",
      "filed": "2026-03-26",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -34473000.0
      },
      "period_end": "2023-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001193125-26-126368",
    "filed": "2026-03-26",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001691082.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0001691082.json"
  },
  "ticker": "LBRX"
}